Management of prosthetic joint infections (PJI) is a challenging task. These infections include different clinical and microbiological settings calling upon various treatment strategies according to infection type (acute or chronic), bone quality, the involved micro-organism and the patient's general condition and willing.
Treatment of PJI combines surgery and prolonged antibiotic therapy. In some patients with a high operative risk prolonged suppressive antibiotic therapy can be used.
Lack of large prospective studies motivated the conception of this cohort with a long term follow up, regardless to PJI management procedures.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient aged over 18 years old with hip, knee and or shoulder joint prosthesis who consented to participate in the study with:
* According to musculoskeletal infection society definition: PJI is present when one of the major criteria exists or four out of six minor criteria.
Major Criteria:
* Two positive periprosthetic cultures with phenotypically identical organisms, OR
* A sinus tract communicating with the joint, OR
Minor Criteria:
* Elevated serum C-reactive protein (CRP) AND erythrocyte sedimentation rate (ESR)
* Elevated synovial fluid white blood cell (WBC)
* Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%)
* The presence of pus in the joint without known cause
* Positive histological analysis of periprosthetic tissue
* A single positive culture
Or a PJI which meets the following three criteria:
* Medical story suggesting prosthetic joint infection.
* The presence of pain either with or without swelling for more than 3 months unrelated to a mechanical cause.
* Germ identification in a single sample of fluid aspiration or tissue culture.
* Or microbial growth in prosthesis sonication fluid culture greater than 50CFU/ml.
Exclusion Criteria:
* Patient who does not meet eligibility criteria.
* Patient lawfully deprived of his liberty.
* Patient not insured under social security scheme.
Primary outcome measure(s)
Number of patients with hip and knee prosthetic joint reinfection (relapse and new infection) and multi-variable analysis of reinfection risk factors — 2 years
Trial sites (1)
Facility
City
Region
Status
Groupe Hospitalier Diaconesses Croix Saint Simon
Paris
Île-de-France Region
Recruiting
More Groupe Hospitalier Diaconesses Croix Saint-Simon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.